戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ite and the primary causative agent of human babesiosis.
2 nts experienced symptoms suggestive of acute babesiosis.
3 producible for use in the diagnosis of acute babesiosis.
4  Lyme disease, 26 (11%) were coinfected with babesiosis.
5 rochetes and the piroplasm that causes human babesiosis.
6 ed in the United States to screen for bovine babesiosis.
7 e in the routine clinical diagnosis of acute babesiosis.
8 ad had a splenectomy and had a fatal case of babesiosis.
9 f an immunosuppressed patient with relapsing babesiosis.
10 better characterize cardiac complications of babesiosis.
11  months after the diagnosis and treatment of babesiosis.
12 f B. burgdorferi may reduce the incidence of babesiosis.
13 asitemia and parasite clearance during acute babesiosis.
14 otential small vessel complications of human babesiosis.
15 fective therapies for the treatment of human babesiosis.
16 be used in control strategies against bovine babesiosis.
17  for optimal use of tafenoquine in relapsing babesiosis.
18 eraged to improve our understanding of human babesiosis.
19 ch causes the most pathogenic form of bovine babesiosis.
20 sis, 0.0012 for ehrlichiosis, and 0.0005 for babesiosis.
21  been addressed in a cohort of patients with babesiosis.
22 tion and in a single human case of relapsing babesiosis.
23 rategies for the diagnosis and management of babesiosis.
24            There is no vaccine against human babesiosis.
25 ind evidence of retinopathy in patients with babesiosis.
26 ith no recrudescence in both models of human babesiosis.
27 e combination therapy for treatment of human babesiosis.
28 pecimens are used to diagnose active HGA and babesiosis.
29 n plus quinine is often used to treat severe babesiosis.
30 small mammals, is the primary cause of human babesiosis.
31 omycin plus atovaquone is effective for mild babesiosis.
32 nt, and prevention of Lyme disease, HGA, and babesiosis.
33 rease in the risk of transfusion-transmitted babesiosis.
34 ephalitis, borreliosis, tick-borne fever and babesiosis.
35 demiology, treatment and prevention of human babesiosis.
36 e basis of effective vaccines against canine babesiosis.
37 lasmosis, cryptosporidiosis, coccidiosis and babesiosis.
38 inical suspicion for transfusion-transmitted babesiosis.
39 ses are involved in protection against acute babesiosis.
40 of the host may influence protection against babesiosis.
41 and adaptive immunity in resistance to acute babesiosis.
42                         For the treatment of babesiosis, a regimen of atovaquone and azithromycin is
43                                   Background Babesiosis, a tickborne zoonotic disease caused by intra
44                                              Babesiosis, a zoonosis caused by the protozoan Babesia m
45 e medical records of all adult patients with babesiosis admitted to Yale-New Haven Hospital from Janu
46 of cardiac complications among patients with babesiosis admitted to Yale-New Haven Hospital over the
47             Transplant patients may contract babesiosis after tick exposure and/or via blood transfus
48 he pathologic symptoms associated with human babesiosis, an emerging disease with worldwide distribut
49 of several zoonoses, including Lyme disease, babesiosis, anaplasmosis, and a viral encephalitis.
50 ity of the PCR-based test with patients with babesiosis and a group of asymptomatic subjects residing
51 ange over time with increased recognition of babesiosis and as the epidemiology of Babesia is impacte
52 s and can infect mice resulting in fulminant babesiosis and death.
53  is an increasingly reported complication of babesiosis and has been described as a severe complicati
54 sess serum proteomic profiles from dogs with babesiosis and healthy dogs using a label-based proteomi
55                   We report a severe case of babesiosis and hemophagocytic syndrome in an asplenic re
56 current therapies for the treatment of human babesiosis and highlight its potential in providing prot
57 diagnosis and treatment of co-infection with babesiosis and Lyme disease will be addressed in a separ
58  activation and erythrocyte cytoadherence in babesiosis and malaria have exploited these similarities
59 ities and differences in the pathogenesis of babesiosis and malaria should lead to additional fundame
60  Babesia and Plasmodium, the agents of human babesiosis and malaria, depend on the salvage or de novo
61 me disease, human granulocytic anaplasmosis, babesiosis and other diseases.
62 at are vectors of important diseases such as babesiosis and theileriosis.
63 ot include comprehensive recommendations for babesiosis and tick-borne rickettsial infections, which
64 omplicated cases and 14 complicated cases of babesiosis) and 20 healthy dogs were included.
65 to the pathological consequences of malaria, babesiosis, and theileriosis.
66 s currently recommended for the treatment of babesiosis are associated with a high failure rate and s
67        Most clinical cases and fatalities of babesiosis are caused by Babesia microti Current treatme
68               Cardiac complications of acute babesiosis are common and occurred in approximately one-
69 , human granulocytic anaplasmosis (HGA), and babesiosis are emerging tick-borne infections.
70 in patients with concurrent Lyme disease and babesiosis are greater than in patients with either infe
71                                  Malaria and babesiosis are significant parasitic infections, requiri
72 aplasmosis, rickettsiosis, ehrlichiosis, and babesiosis are zoonotic and have been cited as the most
73 on potential ophthalmologic complications of babesiosis, but this issue has not previously been addre
74 tive measures for preventing transmission of babesiosis by blood transfusion are needed.
75                        The risk of acquiring babesiosis by blood transfusion is largely unknown since
76 as isolated from a Connecticut resident with babesiosis by hamster inoculation and adapted to C3H/HeJ
77 patients 2 to 4 weeks after the diagnosis of babesiosis, by which time all the patients had had clini
78 enic rupture occurred in approximately 1% of babesiosis cases.
79 ocompromised patients experiencing relapsing babesiosis caused by B. microti.
80  of proteins and pathways involved in canine babesiosis caused by B. rossi have revealed key differen
81 ifferentiation of disease severity in canine babesiosis caused by B. rossi.
82                                        Human babesiosis caused by Babesia microti is an emerging tick
83  Babesia microti Current treatment for human babesiosis consists of two drug combinations, atovaquone
84 orescence, have been used over the years for babesiosis diagnosis, detection of the secreted B. micro
85 te in a cell population using ATR-FTIR for a babesiosis diagnostic.
86 total of 86 patients received a diagnosis of babesiosis during the 7.5-year study period; 18 of these
87 New Haven Hospital with laboratory confirmed babesiosis during the summer of 2023 and obtained inform
88 seful to improve the understanding of canine babesiosis epidemiology and ways to control the disease
89  the United States can have life-threatening babesiosis even though they are seronegative to B. micro
90                      Patients with ICAH with babesiosis experience more severe disease and higher com
91                                              Babesiosis followed its normal course of infection in co
92          Diagnosis and successful therapy of babesiosis following transfusion.
93                                              Babesiosis (formerly known as piroplasmosis) is a tick-b
94 ded adult patients with laboratory-confirmed babesiosis from 2009 to 2023.
95 te babesiosis, we tested patients with acute babesiosis from a site in New England where the disease
96                  The target audience for the babesiosis guideline includes primary care physicians an
97                                              Babesiosis has long been recognized as an economically i
98 ne hemolytic anemia [WAHA]) in patients with babesiosis has not previously been well described.
99                                       Canine babesiosis has recently been recognized as an emerging i
100 e the poor ecological fitness of B. microti, babesiosis has recently emerged in areas endemic for Lym
101 siosis, particularly transfusion-transmitted babesiosis, has been emerging as a major threat to publi
102         In areas where both Lyme disease and babesiosis have been reported, the possibility of concom
103                       Animal models of human babesiosis have provided a basic understanding of the im
104  serve as vectors of pathogens causing human babesiosis, human granulocytic anaplasmosis, and tick-bo
105              We describe a case of relapsing babesiosis in an immunocompromised patient.
106              The incidence and prevalence of babesiosis in animals and humans is increasing, yet prev
107 the parasite, vaccines being used to prevent babesiosis in animals, and lessons from malaria vaccine
108  may result in the appearance of transfusion babesiosis in areas less familiar with these parasites.
109 ctivity with Babesia divergens, which causes babesiosis in cattle and humans in Europe, but that it h
110 Babesia bovis, the causative agent of severe babesiosis in cattle, was previously shown to undergo an
111     Babesia canis is the agent of the canine babesiosis in Europe.
112 de evidence for radical cure of experimental babesiosis in immunodeficient mice using a combination o
113 etts, is the same organism that caused human babesiosis in Missouri and Kentucky, on the basis of mor
114 ck-borne red blood cell parasite that causes babesiosis in people.
115 transmit both strains, resulting in virulent babesiosis in recipients.
116    The duration of antimicrobial therapy for babesiosis in severely immunocompromised patients should
117                                              Babesiosis in sickle cell disease (SCD) is marked by sev
118  in southern New England are coinfected with babesiosis in sites where both diseases are zoonotic.
119                   Physicians should consider babesiosis in the differential diagnosis of a febrile he
120  the impact of simultaneous Lyme disease and babesiosis in the mouse model.
121             The primary etiological agent of babesiosis in the United States is B. microti.
122                                        Human babesiosis in the United States is caused predominantly
123 eased recognition of the prevalence of human babesiosis in the United States, together with rising co
124 iroplasms previously known to cause zoonotic babesiosis in the United States.
125 e, is the primary etiological agent of human babesiosis in the United States.
126 majority of cases of transfusion-transmitted babesiosis in the United States.
127    Babesia duncani is the causative agent of babesiosis in the western United States.
128                        We sought evidence of babesiosis in three residents of New Jersey who were sus
129 tory responses to antimicrobial treatment of babesiosis, including clearance of Babesia microti paras
130 ultiple red blood cell transfusions acquired babesiosis infection with Babesia divergens-like/MO-1 or
131                                              Babesiosis is a disease of significant medically and vet
132                                       Canine babesiosis is a life-threatening haemoparasitic disease
133                                              Babesiosis is a malaria-like disease in humans and anima
134                                        Human babesiosis is a malaria-like illness caused by tick-born
135                                              Babesiosis is a malaria-like illness transmitted by the
136                                        Human babesiosis is a potentially fatal tick-borne disease cau
137                                              Babesiosis is a potentially life-threatening disease cau
138                                              Babesiosis is a tick-borne disease caused by intraerythr
139                                              Babesiosis is a tick-borne disease that is endemic in th
140                                        Human babesiosis is a tick-borne multisystem disease caused by
141                                              Babesiosis is a tick-borne parasitic disease that poses
142                                              Babesiosis is a tick-borne zoonosis caused by protozoans
143                                              Babesiosis is a tick-borne, malaria-like illness known t
144                                        Human babesiosis is a worldwide emerging tick-borne disease ca
145                           PURPOSE OF REVIEW: Babesiosis is a zoonosis, a disease communicable from an
146                                              Babesiosis is also recognized as an emerging zoonosis of
147                                        Human babesiosis is an emerging tick-borne malaria-like illnes
148                                              Babesiosis is an emerging zoonosis and widely distribute
149                                        Human babesiosis is an emerging zoonosis that is transmitted b
150                                              Babesiosis is an emerging zoonosis with important public
151 ng in a region in southern New England where babesiosis is enzootic.
152          The risk of transfusion-transmitted babesiosis is higher than usually appreciated and in end
153     In endemic areas transfusion-transmitted babesiosis is more prevalent than usually believed.
154          Prompt diagnosis is important since babesiosis is responsive to antibiotic therapy and, untr
155 icroti, the primary causative agent of human babesiosis, is a major public health concern in the Unit
156                             The diagnosis of babesiosis may be confused with malaria and should be in
157 ossible cases of Lyme borreliosis (n = 142), babesiosis (n = 41), and HME (n = 21).
158                                    Relapsing babesiosis often occurs in highly immunocompromised pati
159 ens in 58 subjects with non-life-threatening babesiosis on Nantucket, on Block Island, and in souther
160 derstudied zoonotic genus Babesia In humans, babesiosis, particularly transfusion-transmitted babesio
161 S rRNA gene of Babesia microti, the dominant babesiosis pathogen in the United States.
162 y also detected BmGPI12 in the plasma of six babesiosis patients at the time of diagnosis but not in
163 gene sequences of parasite isolates from six babesiosis patients from Nantucket.
164 id not receive specific therapy, symptoms of babesiosis persisted for a mean of 114 days in five subj
165                                              Babesiosis poses significant risks of adverse outcomes i
166                                              Babesiosis, recognized since biblical times as an import
167  high-prevalence area to identify 7 cases of babesiosis-related splenic rupture between 2014 and 2016
168                                Most cases of babesiosis reported in the United States have been tickb
169      Our results indicate that resolution of babesiosis requires CD4 T cells and a novel mechanism of
170 needed to elucidate the relationship between babesiosis severity and cardiac outcomes.
171                                              Babesiosis should be included in the differential diagno
172 the urgent need for more-effective and safer babesiosis therapies.
173 evaluated the retinas of patients with acute babesiosis to determine if retinal abnormalities are a f
174         Here, we report 5 cases of relapsing babesiosis treated with tafenoquine, including the previ
175                                              Babesiosis treatment failures with standard therapy have
176 ick transmission showed no clinical signs of babesiosis, unlike those receiving intravenous challenge
177  relationship, we developed a mouse model of babesiosis using a novel clinical isolate of B. microti.
178                                              Babesiosis, usually caused by the intraerythrocytic para
179 e, we review historic and recent attempts in babesiosis vaccine discovery to avoid past pitfalls, lea
180 efforts to inform the development of a human babesiosis vaccine.
181  to guide the development of next-generation babesiosis vaccines.
182               Conclusions We documented post-babesiosis WAHA in patients who did not have a history o
183                   One patient diagnosed with babesiosis was also seropositive for ehrlichiosis.
184                    A definitive diagnosis of babesiosis was made by microscopic examination of Giemsa
185                                              Babesiosis was negatively associated with mean annual te
186 us diseases (Lyme disease, ehrlichiosis, and babesiosis) was conducted among 230 residents of a semir
187  from Babesia divergens, the agent of bovine babesiosis, was able to induce complete protection again
188 ing data on cases of transfusion-transmitted babesiosis, we compared the proportions of screened vers
189 hat occurred after treatment of patients for babesiosis, we conducted a retrospective cohort study of
190 cent-antibody procedure for diagnosing acute babesiosis, we tested patients with acute babesiosis fro
191 no reported cases of transfusion-transmitted babesiosis were associated with screened donations (i.e.
192 Overall, 29 cases of transfusion-transmitted babesiosis were linked to blood from infected donors, in
193 mplexan parasite Babesia bovis causes bovine babesiosis which leads to enormous food and economic los
194                    One such disease is human babesiosis, which is a rapidly emerging tick-borne illne
195 is, which is caused by Borrelia burgdorferi, babesiosis, which is caused by Babesia microti, and huma
196                    The specific diagnosis of babesiosis, which is caused by the piroplasm Babesia mic
197 ective cohort study of all the patients with babesiosis who were cared for at our center from January
198 interleukin-12 (IL-12) in the model of acute babesiosis with the WA1 Babesia.
199 s for highly immunocompromised patients with babesiosis, with no parasites detected on blood smear fo
200 croti is responsible for most cases of human babesiosis worldwide.
201      If reintroduced into the United States, babesiosis would cause significant mortality in the naiv

 
Page Top